3-(4-Chlorophenyl)-5-[2-(2,4-difluorophenyl)pyrazol-3-yl]-2,1-benzoxazole;5-[2-(2,4-difluorophenyl)pyrazol-3-yl]-3-(4-methoxyphenyl)-2,1-benzoxazole;3-phenyl-5-(2-phenylpyrazol-3-yl)-2,1-benzoxazole

• 分子结构分类: 有机化合物 - 有机杂环化合物 - 唑类
• 英文名称: 3-(4-Chlorophenyl)-5-[2-(2,4-difluorophenyl)pyrazol-3-yl]-2,1-benzoxazole;5-[2-(2,4-difluorophenyl)pyrazol-3-yl]-3-(4-methoxyphenyl)-2,1-benzoxazole;3-phenyl-5-(2-phenylpyrazol-3-yl)-2,1-benzoxazole
• 英文别名: 3-(4-chlorophenyl)-5-[2-(2,4-difluorophenyl)pyrazol-3-yl]-2,1-benzoxazole;5-[2-(2,4-difluorophenyl)pyrazol-3-yl]-3-(4-methoxyphenyl)-2,1-benzoxazole;3-phenyl-5-(2-phenylpyrazol-3-yl)-2,1-benzoxazole
• 化学式: C67H42ClF4N9O4
• 分子量: 1148.5
• InChiKey: OGRGTVVVKRXKLA-UHFFFAOYSA-N

计算性质

• 辛醇/水分配系数(LogP)：
  17.26
• 重原子数：
  85
• 可旋转键数：
  10
• 环数：
  15.0
• sp3杂化的碳原子比例：
  0.01
• 拓扑面积：
  141
• 氢给体数：
  0
• 氢受体数：
  14

文献信息

• [EN] BENZISOXAZOLE MODULATORS OF NEUROGENESIS<br/>[FR] MODULATEURS BENZISOXAZOLE DE LA NEUROGÉNÈSE
  申请人：HOFFMANN LA ROCHE

  公开号：WO2014016267A1

  公开（公告）日：2014-01-30

  The present invention relates to compounds of general formula (I) wherein Ar1/Ar2 are phenyl or a 5 or 6-membered heteroaryl; R1/R2 is hydrogen, halogen, lower alkyl, CF3 or lower alkoxy; n,m are 1 or 2; or to a pharmaceutically acceptable acid addition salt, to a racemic mixture or to its corresponding enantiomer and/or optical isomers thereof, with the exception of the compound 2,1-benzisoxazole,3-(4-chlorophenyl)-5-(1-phenyl-1H-pyrazol-5-yl)-. The compounds may be used for the treatment of schizophrenia, obsessive-compulsive personality disorder, major depression, bipolar disorders, anxiety disorders, normal aging, epilepsy, retinal degeneration, traumatic brain injury, spinal cord injury, post-traumatic stress disorder, panic disorder, Parkinson's disease, dementia, Alzheimer's disease, mild cognitive impairment, chemotherapy-induced cognitive dysfunction, Down syndrome, autism spectrum disorders, hearing loss, tinnitus, spinocerebellar ataxia, amyotrophic lateral sclerosis, multiple sclerosis, Huntington's disease, stroke, radiation therapy, chronic stress, abuse of neuro-active drugs, such as alcohol, opiates, methamphetamine, phencyclidine and cocaine.

  本发明涉及一般式（I）的化合物，其中Ar1/Ar2为苯基或5或6-成员杂环芳基；R1/R2为氢、卤素、较低烷基、三氟甲基或较低烷氧基；n、m为1或2；或者为药学上可接受的酸盐加合物，为外消旋混合物或其相应的对映体和/或光学异构体，但不包括化合物2,1-苯并异噁唑，3-(4-氯苯基)-5-(1-苯基-1H-吡唑-5-基)-。这些化合物可用于治疗精神分裂症、强迫性人格障碍、重性抑郁症、躁郁症、焦虑障碍、正常衰老、癫痫、视网膜退行性疾病、创伤性脑损伤、脊髓损伤、创伤后应激障碍、恐慌障碍、帕金森病、痴呆症、阿尔茨海默病、轻度认知障碍、化疗诱导的认知功能障碍、唐氏综合征、自闭症谱系障碍、听力损失、耳鸣、脊髓小脑共济失调、肌萎缩侧索硬化、多发性硬化、亨廷顿病、中风、放射治疗、慢性应激、滥用神经活性药物，如酒精、鸦片类药物、甲基苯丙胺、非那西丁和可卡因。
• BENZISOXAZOLE MODULATORS OF NEUROGENESIS
  申请人：F.Hoffmann-La Roche AG

  公开号：EP2877466A1

  公开（公告）日：2015-06-03